Pharmacotherapy of Alzheimer disease and neuropsychiatric symptoms of dementia

Iva Prokopová

Prakt. Lékáren. 2018; 14(4e)  

Alzheimer disease is the most prevalent type of dementia. A precise diagnosis is required for effective management. Cholinesterase inhibitorsare used as first line therapy to provide modest symptomatic benefit in some patients, memantine appears to have modest benefits in patients with moderate to severe disease. Neuropsychiatric symptoms are common in dementia and contribute to nursing home admissionand caregiver stress. Identifying the genesis of the abnormal behavior is critical, in order that nonpharmacologic therapies are preferred overmedication. Symptomatic pharmacologic treatment includes antidepressants, antipsychotics, anxiolytics and other...

Primary headaches – treatment today and tomorrow

Jolana Marková, Rudolf Kotas

Prakt. Lékáren. 2018; 14(4e)  

This systematic review summarizes the clinical manifestations and the existing knowledge about the treatment of the most frequent primaryheadaches – migraine, tension type headache and cluster headache. The acute treatment of migraine attacks consists in the use of simple analgesics, non-steroidal anti-inflammatory drugs, ergotamines and triptans. Patients with frequent or long lasting attacks require the prophylactictreatment. So far beta-blockers, antiepileptic drugs, calcium channel blockers and antidepressants are used. Injections of onabotulinumtoxinA reduce the frequency of attacks in chronic migraine. The most promising new approach in...

Antiparkinsonian drugs, mental disorders in patients with Parkinson’s disease and drug -drug interactions

Michal Prokeš, Josef Suchopár

Prakt. Lékáren. 2018; 14(4e)  

Patients with Parkinson´s disease (PN), a common neurodegenerative disorder, suffer not only from movement disorder, but also from mentaldisorders including behavioral disorders and psychosis. These disorders are closely related to dopaminergic treatment of PN. Despite knowledgeof the clinical features of these disorders, many patients may not be diagnosed in time. Another issue are drug-drug interactions, because patientswith PN are treated for associated diseases usually by other physicians, who may not always be aware, that the antiparkinsonian or antipsychotic drugs interact with other commonly prescribed drugs. This article introduces the medical...

Glycemic sensors in treatment of diabetes

Jan Šoupal

Prakt. Lékáren. 2018; 14(4e): e10-e17 | DOI: 10.36290/lek.2018.050  

Successful treatment of Type 1 diabetes (T1D) requires precise insulin dosing and reliable ways of glycemia monitoring. Self-monitoring of bloodglucose (SMBG), Flash glucose monitoring (FGM) and continuous glucose monitoring (CGM) can be used for day-to-day monitoring. The basis of CGM and FGM is glycemic sensor inserted into the subcutaneous tissue. CGM automatically informs the patient about glucose development atapproximately five-minute intervals. With FGM, the patient is informed only after placing the receiver in close proximity to the sensor. The accuracyof both CGM and FGM measurements has improved significantly and has been comparable in recent...

Vedolizumab, its pharmacological profile and therapeutic use

Tomáš Douda

Prakt. Lékáren. 2018; 14(4e)  

Vedolizumab (VDZ), a humanized monoclonal antibody, is approved for use in ulcerative colitis and Crohn’s disease (IBD).Vedolizumab inhibitsleukocyte vascular adhesion and migration into the gastrointestinal tract through α4β7 integrin blockade. Clinical effectiveness of vedolizumabwas evident in both the CD and mainly in UC populations. These findings are consistent with observations from clinical trials, and from real word experience too. The improved safety profile, novel mechanism of action and clinical need for new therapies has led to the rapid adoptionof vedolizumab use in clinical practice.

Preparation of hard gelatin capsules with decreasing diazepam content for treatment of benzodiazepines and Z-hypnotics addiction

Aleš Franc, Jan Elbl, Jan Muselík, Kateřina Kubová, David Vetchý

Prakt. Lékáren. 2018; 14(4e): e50-e56 | DOI: 10.36290/lek.2018.071  

At present, millions of people in the world are addicted to benzodiazepines. The form of both somatic and psychic addiction does not permit immediatediscontinuation of these drugs. One of methods, which has been used successfully for long time, is to switch the patients to diazepam. Diazepamhas long biological half-life and after stabilization, gradual dose reduction until placebo dose is reached can follow. Hard gelatinous capsules seemto be the most suitable dosage forms for this process because they may contain also other drugs alleviating abstinence symptoms – antipsychotics,antidepressants, or beta blockers. Because of low doses of these...

34. Lékárnické dny v krásném Písku, městě patriotů a studentů

PharmDr. Pavel Grodza

Prakt. Lékáren. 2018; 14(4e): e57-e60  

Významné životní jubileum prof. RNDr. Luďka Jahodáře, CSc.

Prakt. Lékáren. 2018; 14(4e): e61-e62  

Vzpomínka na prof. Jana Solicha

PharmDr. Pavel Grodza

Prakt. Lékáren. 2018; 14(4e): e63-e64  

E-verze 4/18

Prakt. Lékáren. 2018; 14(4e)